Effective treatments are lacking for most neurological disorders, and progress in developing new therapeutic agents has been frustratingly slow. Howells and colleagues explore the barriers to the development of treatments for these conditions, focusing predominantly on the stroke field. They highlight the current deficiencies and conflicts of interest in preclinical and clinical research, and suggest ways in which scientific rigour might be improved.
- David W. Howells
- Emily S. Sena
- Malcolm R. Macleod
